Zithromax and Januvia: Two Commonly-Prescribed Drugs Now Shown to Be Killing Patients
On the heels of the first 60 Day Turnaround Class – it is good to support the concerns about medications designed to “HELP” people with high blood sugar (Type II Diabetes), this is the new world of Januvia.
Here is a good portion of the article –
By Dr. Mercola
Recent news again highlights why you’d be well advised to heed early warnings about potentially dangerous drugs.
The first featured article reports that the US Food and Drug Administration (FDA) is now investigating a potential link between a commonly used class of diabetes drugs and pancreatic inflammation and pre-cancerous changes to the pancreas.1
The FDA is also adding a heart-risk warning to the antibiotic Zithromax (azithromycin), better known as the Z-Pak.2
I’ve discussed the dangers of Zithromax before, most recently in December last year, and warned of potential dangers of Januvia all the way back in 2006 — the same drug now being investigated by the FDA for a potential link to pancreatic cancer. I also published a strong warning against this class of drugs last year.
In each case, I presented the evidence against the drugs long before any warnings were issued by the FDA, or action was taken to remove the dangerous drugs from the market.
In the case of Vioxx, my warnings preceded the drug’s eventual removal by five years, but it was too late as the drug had already killed over 60,000 people.
I have no doubt that these newer diabetes drugs will kill tens of thousands of people from cancer before action is taken. There is a good chance the death toll will even exceed that from Vioxx. Hopefully, you or someone you love will not be one of the victims, as you will have this potentially life-saving information.
“Want of foresight, unwillingness to act when action would be simple and effective, lack of clear thinking, confusion of counsel until the emergency comes, until self-preservation strikes its jarring gong – these are the features which constitute the endless repetition of history.” ~ Winston Churchill
FDA Investigates Potential Cancer Link to Popular Diabetes Drugs
According to an FDA notice,3 posted on March 14, the agency is:
“Evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.”
This class of diabetes drugs, known as incretin mimetics, includes:
Exenatide (Byetta, Bydureon) Liraglutide (Victoza) Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync) Saxagliptin (Onglyza, Kombiglyze XR) Alogliptin (Nesina, Kazano, Oseni) Linagliptin (Tradjenta, Jentadueto)
Incretin mimetics (also known as glucagon-like peptide-1 receptor agonist, or GLP-1 agonist, and dipeptidyl peptidase-4 inhibitors, or simply DPP-4 inhibitors), work by mimicking incretin hormones, reducing glucagon levels, and inhibiting the enzyme called DPP-4.
Incretins are a group of gut hormones your body produces naturally to stimulate the release of insulin in response to a meal. So, as your blood sugar rises, the drug prompts your pancreas to release insulin. It also prevents your pancreas from putting out too much glucagon, another hormone, which causes your liver to release stored sugar into your bloodstream.
Another mechanism by which it helps control your blood sugar level is by inhibiting DPP-4 — a protease (an enzyme that chops up protein chains) that, among other things, destroys the hormone GLP-1, which may explain why these drugs appear to be linked to increased cancer risk. (I’ll discuss this more below.)
The medication also slows the rate at which your stomach empties after you’ve eaten a meal, which may reduce feelings of hunger. This dampens the rate at which your blood sugar rises after eating.
The first drug in this class — Sitagliptin, manufactured by Merck and sold under the name Januvia4, 5 — received FDA approval in 2006.6 It is one of the most commonly prescribed drugs for diabetes, which is why it will have such a devastating effect if it not stopped soon. Saxagliptin (Onglyza), another DPP-4 inhibitor, was approved in July 2009, followed by Linagliptin (Trajenta) in 2011. A number of additional DPP-4 inhibitors are currently under development, including a potentially disastrous once-a-week version.